Literature DB >> 29526985

Long Non-Coding RNAs as Key Regulators of Cardiovascular Diseases.

Koh Ono1, Yasuhide Kuwabara1, Takahiro Horie1, Takeshi Kimura1.   

Abstract

Protein-coding genes account for less than 2% of the whole genome. However, the advances in RNA sequencing and genome-wide analysis have demonstrated that most of the genome is capable of being transcribed. Moreover, recent studies have suggested that long non-coding RNAs (lncRNAs) are critical regulators of gene expression and epigenesis in both physiological and disease states. Several lncRNAs are functionally involved in cardiovascular diseases and may be potential therapeutic targets. Here, we review the current strategies for the discovery of functional lncRNAs and recently discovered lncRNAs in the cardiovascular field, focusing on cardiac development, hypertrophy, heart failure, and atherosclerosis. We also discuss the therapeutic potentials of synthetic RNAs to modulate these lncRNAs and future directions in this research field.

Entities:  

Keywords:  Atherosclerosis; Cardiac hypertrophy; Heart failure; Non-coding RNAs

Mesh:

Substances:

Year:  2018        PMID: 29526985     DOI: 10.1253/circj.CJ-18-0169

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  3 in total

1.  Long Noncoding RNA (lncRNA) n379519 Promotes Cardiac Fibrosis in Post-Infarct Myocardium by Targeting miR-30.

Authors:  Xiaxia Wang; Chunming Yong; Kai Yu; Renchao Yu; Rui Zhang; Lingfan Yu; Shan Li; Shanglang Cai
Journal:  Med Sci Monit       Date:  2018-06-11

2.  Screening and functional identification of lncRNAs in antler mesenchymal and cartilage tissues using high-throughput sequencing.

Authors:  Dan-Yang Chen; Ren-Feng Jiang; Yan-Jun Li; Ming-Xiao Liu; Lei Wu; Wei Hu
Journal:  Sci Rep       Date:  2020-06-11       Impact factor: 4.379

3.  A long non-coding RNA GATA6-AS1 adjacent to GATA6 is required for cardiomyocyte differentiation from human pluripotent stem cells.

Authors:  Rajneesh Jha; Dong Li; Qingling Wu; Katherine E Ferguson; Parvin Forghani; Gregory C Gibson; Chunhui Xu
Journal:  FASEB J       Date:  2020-09-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.